AlphAIAlphAI — Financial news for AI agents
haaretz.comOCT 102 min read$TEVA

Israeli Pharma Giant Teva Wins FDA Approval for Monthly Schizophrenia Injection Weltruza

Teva Pharmaceuticals received FDA approval for Weltruza, a monthly schizophrenia injection. The drug, developed with Medincell, will launch in the U.S. soon. Teva may pay Medincell up to $112M in milestones plus royalties. Teva and Medincell shares rose on the news.

Original reporting
haaretz.com
Published Oct 10, 2026, 5:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 10, 2026, 6:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Israeli Pharma Giant Teva Wins FDA Approval for Monthly Schizophrenia Injection Weltruza — source image
Source · haaretz.com
Decision brief

The 30-second read

$TEVABullishHigh
01

Why it matters

The approval expands Teva's portfolio in mental health, potentially increasing its market share and revenue.

02

Market read

New FDA approval is a material catalyst for Teva, likely driving short-term price appreciation.

03

What to watch

Reimbursement negotiations and competition from other long-acting injectables may limit sales.

Relevance 7/10Novelty 8/10Timing: today

Background

Teva's partnership with Medincell previously delivered Uzedy, another long-acting injectable approved in 2023.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

FDA approval of Weltruza, a monthly schizophrenia injection, announced by Teva.

Expected impact

likely upward pressure as investors price in the new drug launch

Evidence & confidence

First-time FDA approval, milestone payments up to $112M, and immediate market reaction (2% rise in Tel Aviv) indicate material impact.

Market effects

Sector

strengthens the psychiatric drug segment and may benefit peers in long-acting antipsychotics

Regional

positive for Israeli pharma and European biotech collaborations

Global

adds to the pipeline of FDA-approved psychiatric treatments worldwide

Counterpoint

What could challenge this read

If the drug fails to gain market uptake, the initial hype could fade quickly.

Key entities

  • Company
    Teva Pharmaceutical Industries Ltd.

    Israeli pharma giant receiving FDA approval.

  • Company
    Medincell

    French biotech partner providing the injection technology.

Read at source← All news

StoryTeva receives FDA approval for Weltruza, the first once‑monthly subcutaneous olanzapine injection

Also covered by

6 outlets

Related articles

OCT 22
$TEVAMed

Once-Monthly Olanzapine for Schizophrenia, With Christoph Correll, MD

Teva Pharmaceuticals' Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia, was approved based on the SOLARIS trial. The trial showed significant symptom reduction compared to placebo. Dr. Christoph Correll, principal investigator, highlighted the benefits of long-acting injectables in reducing relapse and improving patient outcomes. Weltruza's subcutaneous administration aims to address patient reluctance and resource limitations of previous treatments.

hcplive.com2 min
OCT 20
$TEVAMedAI 9/10

Teva, Sanofi Report Sustained Duvakitug Benefits In Phase 2b IBD Study

Teva (TEVA) and Sanofi (SNY) reported positive Phase 2b data for duvakitug, showing sustained benefits in ulcerative colitis and Crohn's disease through Week 44. Clinical remission rates varied by dose, with higher rates observed at 900 mg. The drug was generally well tolerated. Both companies are advancing duvakitug into Phase 3 studies. SNY is up 4.11% at $41.19, while TEVA is down 0.41% at $41.14.

rttnews.com2 min
OCT 20
$TEVAHigh

Teva Pharmaceutical Industries Ltd: UEG Week: Teva and Sanofi's Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn's Disease

Teva Pharmaceuticals and Sanofi reported positive 44-week data for duvakitug, their investigational treatment for ulcerative colitis (UC) and Crohn's disease (CD). The drug showed high rates of clinical remission, response, and endoscopic improvement in both conditions, with a favorable safety profile. Results were presented at UEG Week 2026, and phase 3 trials are ongoing.

finanznachrichten.de2 min